ALHC:NSD-Alignment Healthcare Inc (USD)

COMMON STOCK | Healthcare Plans | NSD

Last Closing Price

USD 7.28

Change

-0.32 (-4.21)%

Market Cap

USD 1.57B

Volume

0.57M

Avg Analyst Target

USD 20.00 (+174.73%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alignment Healthcare Inc (ALHC) Stock Analysis:
Based on the Alignment Healthcare Inc stock forecasts from 6 analysts, the average analyst target price for Alignment Healthcare Inc is USD 20.00 over the next 12 months. Alignment Healthcare Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alignment Healthcare Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Alignment Healthcare Inc’s stock price was USD 7.28. Alignment Healthcare Inc’s stock price has changed by -2.39% over the past week, -5.68% over the past month and +0.00% over the last year.

About

Alignment Healthcare, Inc. operates consumer-centric health care platform. It owns Medicare advantage plan, which are customized to meet the needs of an array of seniors, as well as coordinates and provides covered health care services, including professional, institutional, and ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MGLN Magellan Health Inc

-94.99 (-100.00%)

USD2.50B 8.49 16.66
CLOV Clover Health Investments Corp

-0.10 (-3.47%)

USD1.47B N/A N/A

ETFs Containing ALHC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Healthcare Plans)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.22% 50% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.22% 50% F 1% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.57B 67% D+ 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Healthcare Plans)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.92 33% F 16% F
Price / Cash Flow Ratio 207.77 33% F 2% F
EV/EBITDA 409.08 50% F 3% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -4.50% 33% F 38% F
Return on Assets -1.24% 67% D+ 42% F
Debt to Equity Ratio 470.97% 50% F 4% F
Technical Ratios  
Short Ratio 2.58 67% D+ 46% F
Short Percent 3.98% 100% A+ 39% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector